Abstract
Amylin (islet amyloid polypeptide) and amyloid beta protein (Aβ), identified as proteinaceous deposits within the pancreas of diabetics and the brain of Alzheimer’s patients respectively, share many biophysical, physiological and neurotoxic properties. Although no specific “Aβ receptor” has been identified, emerging evidence suggests that the amylin receptor serves a putative target receptor for the actions of Aβ in the brain. The amylin receptor consists of a calcitonin receptor dimerized with receptor activity-modifying proteins and is widely distributed within central nervous system. Aβ can directly activate this G protein-coupled receptor and trigger multiple intracellular signal transduction messengers and pathways that include calcium, cAMP, ERK1/2 and Fos. Growing evidence suggests that amylin and amylin receptors are involved in many aspects of neurodegenerative pathophysiology. Developing therapeutic strategies aimed at modulating amylin receptor function may prove useful for treatment of neurodegenerative diseases such as Alzheimer’s disease.
Keywords: Alzheimer’s disease, amyloid β (Aβ) protein, calcitonin receptor, calcitonin gene related peptide, diabetes mellitus, human amylin, receptor activity-modifying proteins.
Current Protein & Peptide Science
Title:Role of Amylin and its Receptors in Neurodegeneration
Volume: 14 Issue: 4
Author(s): Wen Fu and Jack H. Jhamandas
Affiliation:
Keywords: Alzheimer’s disease, amyloid β (Aβ) protein, calcitonin receptor, calcitonin gene related peptide, diabetes mellitus, human amylin, receptor activity-modifying proteins.
Abstract: Amylin (islet amyloid polypeptide) and amyloid beta protein (Aβ), identified as proteinaceous deposits within the pancreas of diabetics and the brain of Alzheimer’s patients respectively, share many biophysical, physiological and neurotoxic properties. Although no specific “Aβ receptor” has been identified, emerging evidence suggests that the amylin receptor serves a putative target receptor for the actions of Aβ in the brain. The amylin receptor consists of a calcitonin receptor dimerized with receptor activity-modifying proteins and is widely distributed within central nervous system. Aβ can directly activate this G protein-coupled receptor and trigger multiple intracellular signal transduction messengers and pathways that include calcium, cAMP, ERK1/2 and Fos. Growing evidence suggests that amylin and amylin receptors are involved in many aspects of neurodegenerative pathophysiology. Developing therapeutic strategies aimed at modulating amylin receptor function may prove useful for treatment of neurodegenerative diseases such as Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Fu Wen and Jhamandas H. Jack, Role of Amylin and its Receptors in Neurodegeneration, Current Protein & Peptide Science 2013; 14 (4) . https://dx.doi.org/10.2174/13892037113149990051
DOI https://dx.doi.org/10.2174/13892037113149990051 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nuclear Receptors as Potential Molecular Targets in Cholesterol Accumulation Conditions: Insights from Evidence on Hepatic Cholesterol Degradation and Gallstone Disease in Humans
Current Medicinal Chemistry Improving Brain Drug Targeting Through Exploitation of The Nose-to- Brain Route: A Physiological and Pharmacokinetic Perspective
Current Drug Delivery Preface:
CNS & Neurological Disorders - Drug Targets Development of Subjective Cognitive Decline
Neuroscience and Biomedical Engineering (Discontinued) Problems in Statistical Analysis of Attrition in Randomized Controlled Clinical Trials of Antidepressant for Geriatric Depression
Current Psychiatry Reviews Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”
Recent Patents on Anti-Infective Drug Discovery Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Extracellular Vesicles in the Treatment of Parkinson’s Disease: A Review
Current Medicinal Chemistry Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT)
Current Topics in Medicinal Chemistry Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease
Current Topics in Medicinal Chemistry Targeting PPARalpha in Alzheimer's Disease
Current Alzheimer Research Combination Therapy of Inhaled Corticosteroids and Long-Acting β2- Adrenergics In Management of Patients with Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Design Cognitive Function and Quality of Life in Mild Thyroid Hormone Deficiency
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) The Glial Sodium-Calcium Exchanger: A New Target for Nitric Oxide- Mediated Cellular Toxicity
Current Protein & Peptide Science Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets